QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
NASDAQ:JYNT

Joint (JYNT) Stock Forecast, Price & News

$9.32
-0.37 (-3.82%)
(As of 09/25/2023 ET)
Compare
Today's Range
$9.30
$9.78
50-Day Range
$9.11
$14.09
52-Week Range
$8.76
$20.00
Volume
121,573 shs
Average Volume
140,787 shs
Market Capitalization
$136.82 million
P/E Ratio
44.38
Dividend Yield
N/A
Price Target
$21.00

Joint MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
125.3% Upside
$21.00 Price Target
Short Interest
Bearish
6.63% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.78mentions of Joint in the last 14 days
Based on 9 Articles This Week
Insider Trading
Acquiring Shares
$8.88 M Bought Last Quarter
Proj. Earnings Growth
-30.43%
From $0.23 to $0.16 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

428th out of 961 stocks

Patent Owners & Lessors Industry

4th out of 6 stocks


JYNT stock logo

About Joint (NASDAQ:JYNT) Stock

The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics. The company operates in two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and regional developers. As of March 1, 2022, the company operated approximately 700 locations in the United States. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.

JYNT Price History

JYNT Stock News Headlines

Joint (NASDAQ:JYNT) Coverage Initiated by Analysts at Craig Hallum
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
The Joint Corp. (NASDAQ:JYNT) Sees Large Increase in Short Interest
Lake Street Capital Cuts Joint (NASDAQ:JYNT) Price Target to $30.00
Roth Mkm Lowers Joint (NASDAQ:JYNT) Price Target to $13.00
New Breakthrough "Living Software" Has Been…
New Breakthrough "Living Software" Has Been... Ukraine's "Secret Weapon" Against Russia The Washington Post Reports: "It's a big reason David is beating Goliath..." The Wall Street Journal Reports: "it's a technical revolution." Jeff Bezos Said: "It's in the realm of science fiction." Early investors can reap 5,633% gains on the small company revolutionizing warfare >>>
Joint (JYNT) Gets a Hold from Maxim Group
The Joint (JYNT) Q2 Earnings Miss Estimates, 2023 View Down
Joint Corp. to Cull About 10% of Owned or Managed Clinics
572K Reasons To Be Bullish On Joint Stock
Maxim Group Downgrades Joint (JYNT)
Joint reports Q2 operating highlights
See More Headlines
Receive JYNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Joint and its competitors with MarketBeat's FREE daily newsletter.

JYNT Company Calendar

Last Earnings
9/13/2023
Today
9/25/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Patent owners & lessors
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:JYNT
Employees
359
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$21.00
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+125.3%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Net Income
$1.18 million
Pretax Margin
4.89%

Debt

Sales & Book Value

Annual Sales
$101.91 million
Cash Flow
$0.58 per share
Book Value
$2.23 per share

Miscellaneous

Free Float
14,092,000
Market Cap
$136.82 million
Optionable
Not Optionable
Beta
1.44
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Peter D. Holt (Age 64)
    CEO, Pres & Director
    Comp: $469.55k
  • Jake  SingletonJake Singleton (Age 41)
    Chief Financial Officer
    Comp: $280.92k
  • Mr. Jorge Armenteros
    Sr. VP of Operations
  • Mr. Charles Nelles
    Chief Technology Officer
  • Dr. Steven Knauf
    VP of Chiropractic & Compliance
  • Ms. Lori I. Abou Habib (Age 43)
    Chief Marketing Officer
  • Ms. Krischelle Tennessen
    Chief HR Officer
  • Mr. Craig P. Colmar J.D. (Age 70)
    Sec.













JYNT Stock - Frequently Asked Questions

Should I buy or sell Joint stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Joint in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" JYNT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in JYNT, but not buy additional shares or sell existing shares.
View JYNT analyst ratings
or view top-rated stocks.

What is Joint's stock price forecast for 2023?

4 brokers have issued 12-month price objectives for Joint's stock. Their JYNT share price forecasts range from $13.00 to $30.00. On average, they anticipate the company's stock price to reach $21.00 in the next twelve months. This suggests a possible upside of 125.3% from the stock's current price.
View analysts price targets for JYNT
or view top-rated stocks among Wall Street analysts.

How have JYNT shares performed in 2023?

Joint's stock was trading at $13.98 at the start of the year. Since then, JYNT stock has decreased by 33.3% and is now trading at $9.32.
View the best growth stocks for 2023 here
.

Are investors shorting Joint?

Joint saw a increase in short interest in August. As of August 31st, there was short interest totaling 942,100 shares, an increase of 8.0% from the August 15th total of 872,200 shares. Based on an average daily volume of 125,700 shares, the short-interest ratio is currently 7.5 days. Approximately 6.6% of the shares of the stock are sold short.
View Joint's Short Interest
.

When is Joint's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our JYNT earnings forecast
.

How were Joint's earnings last quarter?

The Joint Corp. (NASDAQ:JYNT) announced its quarterly earnings results on Wednesday, September, 13th. The company reported ($0.01) EPS for the quarter, missing analysts' consensus estimates of $0.01 by $0.02. The company had revenue of $29.31 million for the quarter, compared to analyst estimates of $29.85 million. Joint had a net margin of 2.81% and a trailing twelve-month return on equity of 9.54%.

What guidance has Joint issued on next quarter's earnings?

Joint issued an update on its FY 2023 earnings guidance on Wednesday, September, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $115.00 million-$118.00 million, compared to the consensus revenue estimate of $123.94 million.

What is Peter D. Holt's approval rating as Joint's CEO?

87 employees have rated Joint Chief Executive Officer Peter D. Holt on Glassdoor.com. Peter D. Holt has an approval rating of 59% among the company's employees. This puts Peter D. Holt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Joint own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Joint investors own include Aurora Cannabis (ACB), Advanced Micro Devices (AMD), RTX (RTX), Salesforce (CRM), Mastercard (MA), Starbucks (SBUX), Twitter (TWTR), Viking Therapeutics (VKTX), AbbVie (ABBV) and Adobe (ADBE).

When did Joint IPO?

(JYNT) raised $20 million in an initial public offering (IPO) on Tuesday, November 11th 2014. The company issued 3,000,000 shares at $6.50 per share. Roth Capital Partners and Feltl and Company acted as the underwriters for the IPO and Sanders Morris Harris was co-manager.

What is Joint's stock symbol?

Joint trades on the NASDAQ under the ticker symbol "JYNT."

Who are Joint's major shareholders?

Joint's stock is owned by many different retail and institutional investors. Top institutional shareholders include Bandera Partners LLC (18.05%), BlackRock Inc. (6.95%), Skylands Capital LLC (2.74%), Goldman Sachs Group Inc. (2.38%), Geode Capital Management LLC (1.91%) and O Brien Greene & Co. Inc (1.86%). Insiders that own company stock include Bandera Partners Llc, Glenn J Krevlin, Jake Singleton, James H Amos Jr, Matthew E Rubel, Matthew E Rubel, Peter D Holt and Ronald V Davella.
View institutional ownership trends
.

How do I buy shares of Joint?

Shares of JYNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Joint's stock price today?

One share of JYNT stock can currently be purchased for approximately $9.32.

How much money does Joint make?

Joint (NASDAQ:JYNT) has a market capitalization of $136.82 million and generates $101.91 million in revenue each year. The company earns $1.18 million in net income (profit) each year or $0.21 on an earnings per share basis.

How many employees does Joint have?

The company employs 359 workers across the globe.

How can I contact Joint?

Joint's mailing address is 16767 N PERIMETER DRIVE SUITE 240, SCOTTSDALE AZ, 85260. The official website for the company is www.thejoint.com. The company can be reached via phone at (480) 245-5960, via email at thejoint@lhai.com, or via fax at 480-513-7989.

This page (NASDAQ:JYNT) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -